balaji pharmaceutical ltd Company Information
Company Number
06863514
Website
-Registered Address
3 the oval, sidcup, kent, DA15 9ER
Industry
Dispensing chemist in specialised stores
Telephone
02083021862
Next Accounts Due
December 2024
Group Structure
View All
Shareholders
sajal patel 50%
dipesh praful patel 50%
balaji pharmaceutical ltd Estimated Valuation
Pomanda estimates the enterprise value of BALAJI PHARMACEUTICAL LTD at £326k based on a Turnover of £1.2m and 0.28x industry multiple (adjusted for size and gross margin).
balaji pharmaceutical ltd Estimated Valuation
Pomanda estimates the enterprise value of BALAJI PHARMACEUTICAL LTD at £0 based on an EBITDA of £-47.9k and a 4.09x industry multiple (adjusted for size and gross margin).
balaji pharmaceutical ltd Estimated Valuation
Pomanda estimates the enterprise value of BALAJI PHARMACEUTICAL LTD at £252.4k based on Net Assets of £101.6k and 2.48x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Balaji Pharmaceutical Ltd Overview
Balaji Pharmaceutical Ltd is a live company located in kent, DA15 9ER with a Companies House number of 06863514. It operates in the dispensing chemist in specialised stores sector, SIC Code 47730. Founded in March 2009, it's largest shareholder is sajal patel with a 50% stake. Balaji Pharmaceutical Ltd is a established, small sized company, Pomanda has estimated its turnover at £1.2m with high growth in recent years.
Upgrade for unlimited company reports & a free credit check
Balaji Pharmaceutical Ltd Health Check
Pomanda's financial health check has awarded Balaji Pharmaceutical Ltd a 2 rating. We use a traffic light system to show it exceeds the industry average on 2 measures and has 7 areas for improvement. Company Health Check FAQs
2 Strong
3 Regular
7 Weak
Size
annual sales of £1.2m, make it smaller than the average company (£11.5m)
- Balaji Pharmaceutical Ltd
£11.5m - Industry AVG
Growth
3 year (CAGR) sales growth of 19%, show it is growing at a faster rate (5.3%)
- Balaji Pharmaceutical Ltd
5.3% - Industry AVG
Production
with a gross margin of 27.3%, this company has a comparable cost of product (31.8%)
- Balaji Pharmaceutical Ltd
31.8% - Industry AVG
Profitability
an operating margin of -5.7% make it less profitable than the average company (3.4%)
- Balaji Pharmaceutical Ltd
3.4% - Industry AVG
Employees
with 14 employees, this is below the industry average (81)
14 - Balaji Pharmaceutical Ltd
81 - Industry AVG
Pay Structure
on an average salary of £22k, the company has an equivalent pay structure (£22k)
- Balaji Pharmaceutical Ltd
£22k - Industry AVG
Efficiency
resulting in sales per employee of £83.9k, this is less efficient (£134.1k)
- Balaji Pharmaceutical Ltd
£134.1k - Industry AVG
Debtor Days
it gets paid by customers after 62 days, this is later than average (31 days)
- Balaji Pharmaceutical Ltd
31 days - Industry AVG
Creditor Days
its suppliers are paid after 64 days, this is close to average (69 days)
- Balaji Pharmaceutical Ltd
69 days - Industry AVG
Stock Days
it holds stock equivalent to 18 days, this is less than average (30 days)
- Balaji Pharmaceutical Ltd
30 days - Industry AVG
Cash Balance
has cash to cover current liabilities for 0 weeks, this is less cash available to meet short term requirements (15 weeks)
0 weeks - Balaji Pharmaceutical Ltd
15 weeks - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 84.5%, this is a higher level of debt than the average (61.6%)
84.5% - Balaji Pharmaceutical Ltd
61.6% - Industry AVG
BALAJI PHARMACEUTICAL LTD financials
Balaji Pharmaceutical Ltd's latest turnover from March 2023 is estimated at £1.2 million and the company has net assets of £101.6 thousand. According to their latest financial statements, Balaji Pharmaceutical Ltd has 14 employees and maintains cash reserves of £2.5 thousand as reported in the balance sheet.
Data source: Companies House, Pomanda Estimates
Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 | Mar 2014 | Mar 2013 | Mar 2012 | Mar 2011 | Mar 2010 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Turnover | ||||||||||||||
Other Income Or Grants | ||||||||||||||
Cost Of Sales | ||||||||||||||
Gross Profit | ||||||||||||||
Admin Expenses | ||||||||||||||
Operating Profit | ||||||||||||||
Interest Payable | ||||||||||||||
Interest Receivable | ||||||||||||||
Pre-Tax Profit | ||||||||||||||
Tax | ||||||||||||||
Profit After Tax | ||||||||||||||
Dividends Paid | ||||||||||||||
Retained Profit | ||||||||||||||
Employee Costs | ||||||||||||||
Number Of Employees | 14 | 10 | 10 | 9 | 9 | 10 | 10 | |||||||
EBITDA* |
* Earnings Before Interest, Tax, Depreciation and Amortisation
Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 | Mar 2014 | Mar 2013 | Mar 2012 | Mar 2011 | Mar 2010 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Tangible Assets | 409,743 | 407,236 | 407,577 | 406,726 | 3,301 | 4,045 | 4,810 | 5,937 | 7,916 | 10,554 | 14,072 | 0 | 0 | 0 |
Intangible Assets | 0 | 17,001 | 34,000 | 51,000 | 68,000 | 84,999 | 101,999 | 118,999 | 135,999 | 152,999 | 169,999 | 0 | 0 | 0 |
Investments & Other | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Debtors (Due After 1 year) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Total Fixed Assets | 409,743 | 424,237 | 441,577 | 457,726 | 71,301 | 89,044 | 106,809 | 124,936 | 143,915 | 163,553 | 184,071 | 0 | 0 | 0 |
Stock & work in progress | 42,750 | 33,332 | 41,257 | 53,471 | 57,380 | 62,383 | 72,750 | 79,950 | 77,500 | 75,000 | 72,500 | 62,000 | 0 | 0 |
Trade Debtors | 200,083 | 196,098 | 198,175 | 151,297 | 75,732 | 116,101 | 137,938 | 136,665 | 162,054 | 155,941 | 166,489 | 233,727 | 0 | 0 |
Group Debtors | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Misc Debtors | 0 | 0 | 0 | 0 | 65,083 | 39,209 | 29,935 | 13,060 | 0 | 0 | 0 | 11,451 | 0 | 0 |
Cash | 2,467 | 31,409 | 24,196 | 2,496 | 885 | 911 | 1,761 | 3,354 | 1,068 | 4,524 | 8,580 | 4,302 | 0 | 0 |
misc current assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
total current assets | 245,300 | 260,839 | 263,628 | 207,264 | 199,080 | 218,604 | 242,384 | 233,029 | 240,622 | 235,465 | 247,569 | 311,480 | 0 | 0 |
total assets | 655,043 | 685,076 | 705,205 | 664,990 | 270,381 | 307,648 | 349,193 | 357,965 | 384,537 | 399,018 | 431,640 | 311,480 | 0 | 0 |
Bank overdraft | 0 | 0 | 0 | 0 | 13,931 | 13,021 | 13,239 | 4,080 | 0 | 0 | 0 | 0 | 0 | 0 |
Bank loan | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Trade Creditors | 149,707 | 104,121 | 134,189 | 121,469 | 84,613 | 122,198 | 135,738 | 162,178 | 230,111 | 219,431 | 215,993 | 286,592 | 0 | 0 |
Group/Directors Accounts | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
other short term finances | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
hp & lease commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
other current liabilities | 0 | 0 | 0 | 0 | 20,618 | 37,511 | 82,367 | 56,589 | 0 | 0 | 0 | 0 | 0 | 0 |
total current liabilities | 149,707 | 104,121 | 134,189 | 121,469 | 119,162 | 172,730 | 231,344 | 222,847 | 230,111 | 219,431 | 215,993 | 286,592 | 0 | 0 |
loans | 0 | 0 | 0 | 0 | 20,913 | 25,549 | 29,862 | 34,033 | 0 | 0 | 0 | 0 | 0 | 0 |
hp & lease commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accruals and Deferred Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
other liabilities | 403,711 | 413,292 | 453,764 | 478,829 | 48,896 | 0 | 0 | 42,504 | 104,879 | 138,088 | 184,936 | 0 | 0 | 0 |
provisions | 0 | 0 | 632 | 470 | 627 | 769 | 962 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
total long term liabilities | 403,711 | 413,292 | 454,396 | 479,299 | 70,436 | 26,318 | 30,824 | 76,537 | 104,879 | 138,088 | 184,936 | 0 | 0 | 0 |
total liabilities | 553,418 | 517,413 | 588,585 | 600,768 | 189,598 | 199,048 | 262,168 | 299,384 | 334,990 | 357,519 | 400,929 | 286,592 | 0 | 0 |
net assets | 101,625 | 167,663 | 116,620 | 64,222 | 80,783 | 108,600 | 87,025 | 58,581 | 49,547 | 41,499 | 30,711 | 24,888 | 0 | 0 |
total shareholders funds | 101,625 | 167,663 | 116,620 | 64,222 | 80,783 | 108,600 | 87,025 | 58,581 | 49,547 | 41,499 | 30,711 | 24,888 | 0 | 0 |
Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 | Mar 2014 | Mar 2013 | Mar 2012 | Mar 2011 | Mar 2010 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Activities | ||||||||||||||
Operating Profit | ||||||||||||||
Depreciation | 1,830 | 995 | 1,110 | 826 | 1,101 | 1,348 | 1,603 | 2,638 | 3,518 | 4,691 | 0 | |||
Amortisation | 17,001 | 16,999 | 17,000 | 17,000 | 17,000 | 17,000 | 17,000 | 17,000 | 17,000 | 0 | 0 | |||
Tax | ||||||||||||||
Stock | 9,418 | -7,925 | -12,214 | -3,909 | -5,003 | -10,367 | -7,200 | 2,450 | 2,500 | 2,500 | 10,500 | 62,000 | 0 | 0 |
Debtors | 3,985 | -2,077 | 46,878 | 10,482 | -14,495 | -12,563 | 18,148 | -12,329 | 6,113 | -10,548 | -78,689 | 245,178 | 0 | 0 |
Creditors | 45,586 | -30,068 | 12,720 | 36,856 | -37,585 | -13,540 | -26,440 | -67,933 | 10,680 | 3,438 | -70,599 | 286,592 | 0 | 0 |
Accruals and Deferred Income | 0 | 0 | 0 | -20,618 | -16,893 | -44,856 | 25,778 | 56,589 | 0 | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes & Provisions | 0 | -632 | 162 | -157 | -142 | -193 | 962 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash flow from operations | ||||||||||||||
Investing Activities | ||||||||||||||
capital expenditure | ||||||||||||||
Change in Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
cash flow from investments | ||||||||||||||
Financing Activities | ||||||||||||||
Bank loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Group/Directors Accounts | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Short Term Loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long term loans | 0 | 0 | 0 | -20,913 | -4,636 | -4,313 | -4,171 | 34,033 | 0 | 0 | 0 | 0 | 0 | 0 |
Hire Purchase and Lease Commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
other long term liabilities | -9,581 | -40,472 | -25,065 | 429,933 | 48,896 | 0 | -42,504 | -62,375 | -33,209 | -46,848 | 184,936 | 0 | 0 | 0 |
share issue | ||||||||||||||
interest | ||||||||||||||
cash flow from financing | ||||||||||||||
cash and cash equivalents | ||||||||||||||
cash | -28,942 | 7,213 | 21,700 | 1,611 | -26 | -850 | -1,593 | 2,286 | -3,456 | -4,056 | 4,278 | 4,302 | 0 | 0 |
overdraft | 0 | 0 | 0 | -13,931 | 910 | -218 | 9,159 | 4,080 | 0 | 0 | 0 | 0 | 0 | 0 |
change in cash | -28,942 | 7,213 | 21,700 | 15,542 | -936 | -632 | -10,752 | -1,794 | -3,456 | -4,056 | 4,278 | 4,302 | 0 | 0 |
balaji pharmaceutical ltd Credit Report and Business Information
Balaji Pharmaceutical Ltd Competitor Analysis
Perform a competitor analysis for balaji pharmaceutical ltd by selecting its closest rivals, whether from the WHOLESALE AND RETAIL TRADE; REPAIR OF MOTOR VEHICLES AND MOTORCYCLES sector, other small companies, companies in DA15 area or any other competitors across 12 key performance metrics.
balaji pharmaceutical ltd Ownership
BALAJI PHARMACEUTICAL LTD group structure
Balaji Pharmaceutical Ltd has no subsidiary companies.
Ultimate parent company
BALAJI PHARMACEUTICAL LTD
06863514
balaji pharmaceutical ltd directors
Balaji Pharmaceutical Ltd currently has 2 directors. The longest serving directors include Mrs Sajal Patel (Mar 2009) and Mr Dipesh Patel (Feb 2023).
officer | country | age | start | end | role |
---|---|---|---|---|---|
Mrs Sajal Patel | England | 49 years | Mar 2009 | - | Director |
Mr Dipesh Patel | England | 51 years | Feb 2023 | - | Director |
P&L
March 2023turnover
1.2m
+35%
operating profit
-66.8k
0%
gross margin
27.4%
-0.59%
turnover
Turnover, or revenue, is the amount of sales generated by a company within the financial year.
Balance Sheet
March 2023net assets
101.6k
-0.39%
total assets
655k
-0.04%
cash
2.5k
-0.92%
net assets
Total assets minus all liabilities
balaji pharmaceutical ltd company details
company number
06863514
Type
Private limited with Share Capital
industry
47730 - Dispensing chemist in specialised stores
incorporation date
March 2009
age
15
incorporated
UK
ultimate parent company
accounts
Unaudited Abridged
last accounts submitted
March 2023
previous names
N/A
accountant
DOSHI & CO
auditor
-
address
3 the oval, sidcup, kent, DA15 9ER
Bank
-
Legal Advisor
-
balaji pharmaceutical ltd Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We found 3 charges/mortgages relating to balaji pharmaceutical ltd. Currently there are 3 open charges and 0 have been satisfied in the past.
balaji pharmaceutical ltd Companies House Filings - See Documents
date | description | view/download |
---|